HMGCR and B-cell chronic lymphocytic leukemia: To compare the activity of this pathway between HD and CLL T cells, we targeted two distinct enzymatic steps and evaluated proliferation, using a SQLE inhibitor (NB598) and an HMG-CoA reductase inhibitor (simvastatin) during PBMC simulation.